Cambridge Cardiac Care Centre

Our Research Studies

Want to enrol in a clinical trial?

Participating in a clinical research study provides exciting opportunities to be a part of history in the making as well as providing unique access to novel technologies and therapies that are not otherwise available to patients at large. It does, however, require thoughtful consideration. Talk with your doctor and family members before deciding to enrol. Either you or your doctor may contact our research staff for more information and to discuss any studies that may be suitable for you specifically.

Wave graphic IMG 1799

BRAIN AF

A study involving patients with Atrial Fibrillation and a CHADS2 score of 0. This multicenter, randomized, double-blind clinical trial explores the efficacy and safety of Rivaroxaban (a Factor Xa Inhibitor) as compared to standard of care in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline,

Wave graphic P1010798

Finearts

A study involving HFpEF, Heart Failure patients with an ejection fraction greater than or equal to 40%. This randomized, double-blind, double-dummy, multi-centre Phase 3 clinical trial studies the efficacy and safety of Finerenone, taken once daily. The study monitors effects on symptoms, morbidity and mortality reduction.

Wave graphic PA160495

FRESH

A study involving difficult-to-treat or Resistant Hypertension cases. This phase 3, double-blind, placebo-controlled clinical trial studies the efficacy and safety of Firibistat (QGC001) as administered orally, twice daily, over 12 weeks to resistant-hypertension patients.

Wave graphic IMG 1799

NODE 303

A study involving patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients with symptomatic heart failure or who have syncope/hypotension with SVT will not be recruited in this case. This multi-centre, open-label, Phase 3 study monitors the safety of Etripamil nasal spray for the termination of PSVT. Monitoring of symptoms is…

Wave graphic Pexels pixabay 40568

RAPID NODE 301

A study involving patients with Paroxysmal Supraventricular Tachycardia (PSVT). Patients with symptomatic heart failure or who have syncope/hypotension with SVT will not be recruited in this case. This double-blind, placebo-controlled, phase 3 trial studies the efficacy and safety of Etripamil Nasal Spray for the termination of PSVT. This study…

Wave graphic DSC 6782 Version 2

Realize-K

A study involving patients with symptomatic Heart Failure with reduced Ejection Fraction and Receiving Spironolactonehase IV. This double-blind, placebo-controlled, randomized-withdrawal trial evaluates the use of Sodium Zirconium Cyclosilicate (SZC) for the management of Hyperkalemia in this patient population.

Wave graphic 080136

REFINE ICD

A study involving heart attack patients who have reduced heart pumping function (LVEF between 36% to 50%). This international, multi-centre trial assesses the use of prophylactic ICD therapy to reduce the risk of sudden cardiac death.

Wave graphic IMG 1799

REFRESH

A study involving difficult-to-treat or Resistant Hypertension cases. This phase 3, double-blind, placebo-controlled and open-label clinical trial studies the efficacy and long-term safety of Firibistat (QGC001) as administered orally, once daily.

Wave graphic Medical equipment 2021 08 30 06 54 00 utc

SOS AMI

A study involving patients with a recent history of acute myocardial infarction. This phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study evaluates the efficacy and safety of self-administered subcutaneous Selatogrel for prevention of all-cause death and treatment of acute myocardial infarction.

Wave graphic Exercise bike 2

STEP HFpEF

A study involving patients with obesity-related heart failure who have a preserved ejection fraction and do not have diabetes. This phase 3a, randomized, placebo-controlled, double-blinded, multi-centre clinical trial compares Semaglutide with placebo as related to worsening heart failure symptoms and weight loss.

Wave graphic ECG

STEP HFpEF DM

A study involving patients with obesity-related heart failure who have a preserved ejection fraction and type 2 diabetes. This phase 3a, randomized, placebo-controlled, double-blinded, multi-centre clinical trial compares Semaglutide with placebo as related to worsening heart failure symptoms and weight loss.

Wave graphic P1010798

VICTOR

A study involving adults with chronic Heart Failure with reduced Ejection Fraction. This pivotal phase 3, randomized, placebo-controlled, clinical study evaluates the efficacy and safety of the sGC Stimulator Vericiguat/MK-1242 in in this patient population.

Wave graphic 080136

DELIVER

A phase 3 study assessing the impact of Dapagliflozin, an SGLT2 inhibitor, on reduction of cardiovascular events and worsening heart failure in patients with heart failure with preserved ejection fraction. This study is finished enrolling and is in follow-up.

Wave graphic Pexels pixabay 40568

Empa Kidney

A randomized, double-blind, placebo-controlled trial of Empagliflozin in people with chronic kidney disease, with or without diabetes, to assess if Empagliflozin reduces the risk of kidney disease progression or cardiovascular death. This study is finished enrolling and is in follow-up.

Wave graphic P1010798

Esperion

A randomized, double-blind, placebo-controlled study to assess the effects of Bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in statin intolerant patients with, or at high risk of developing, cardiovascular disease. This study is finished enrolling and is in follow-up.

Wave graphic DSC 6782 Version 2

Heart-Fid

A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (Ferric Carboxymaltose) as treatment for Heart Failure with iron deficiency. This study is finished enrolling and is in follow-up.

Wave graphic Clipboard with hallway in view

Prominent

A randomized, double-blind, placebo-controlled, event-driven efficacy and safety study to assess if Pemafibrate reduces cardiovascular outcomes by reducing triglycerides in patients with diabetes. This study is finished enrolling and is in follow-up

Wave graphic Medical doctors stethoscope 2021 08 26 15 45 56 utc

SELECT

A phase 3 study assessing the impact of Semaglutide, a GLP1 receptor agonist, on weightloss and the recurrence of cardiovascular events in patients with atherosclerotic cardiovascular disease without diabetes. This study is finished enrolling and is in follow-up.

Wave graphic P1010798

SURPASS

A phase 3 study assessing the effects of Tirzepatide, a GIP and GLP1 receptor agonist, in reducing future cardiovascular events in patients with diabetes and established cardiovascular disease . This study is finished enrolling and is in follow up.

  • (OSLER)Amgen

  • Accelerate

  • Active (A & I)

  • AIM HIGH

  • AKCEA

  • Alecardio

  • AlePrevent

  • ALOFT

  • Altitude

  • Amgen (Decartes)

  • Amgen (OSLER II )

  • Amgen Phase III (La Place II)

  • APPRAISE 2

  • Arise -Focus

  • Aristotle

  • Armada Registry

  • Assert II

  • Astronomer

  • ATLAS

  • Atmosphere

  • Averroes

  • Aware AF Program

  • Beautiful

  • BEST

  • BP EASE

  • CAIN

  • Camellia TIMI 61

  • CANTOS OLE

  • Carolina

  • Clarify Registry

  • Class Act

  • Cogentus

  • Cogentus con…

  • Commander

  • COMPASS LTOLE

  • Confidence 2

  • CTAF-2

  • CV Mobius Registry

  • CVEA 2303 **

  • Dal Outcomes Roche

  • Dal Plaque 2

  • Dapa HF Outcomes

  • DAR 311/ E

  • DECLARE ( TIMI 58 )

  • DELIGHT

  • DERIVE

  • Discovery

  • DM 71-05-01

  • DYSIS

  • Electra/DRONE

  • Emperor HF ( HFrEF )

  • Excel

  • Eze(stat) II

  • Ezetrol

  • FOCUS

  • Fourier (AMGEN )

  • Galactic HF

  • GARFIELD Registry

  • Genetic AF

  • Gloria Registry

  • GOALProgram

  • HAT

  • HTN-A-Fib PILOT

  • I-Search

  • Improve-IT

  • INVESTED

  • Iris *fininshed**

  • ISH

  • Jupiter

  • LCZ696A 2201 US

  • LTOLE

  • LTS (Oydssey)

  • Mavik (TORY)

  • Merck 162 (Switch)

  • Merck 4448

  • NODE 302 ( open label )

  • Oberon/ Obelix

  • Odysseus

  • Odyssey Outcomes

  • PACT

  • Pallas

  • Pandora LCZ-

  • Paradigm

  • Paragon

  • PARASAIL

  • Pegasus -TIMI 54

  • PNAI_MNA_001

  • POWER

  • RE-LY

  • Reached

  • React Program

  • REDEEM

  • RELY-ABLE

  • REVEAL - TIMI 55

  • Rocket 81408

  • RUBY 1

  • SAALT

  • SOLID- TIMI 52

  • Soloist

  • SPIRE 1

  • SPIRE 2

  • Study 112 Elderly

  • Study 79 (Tempo)

  • Study 90 (EZEPATH)

  • Sure Registry (25)

  • TECOS (TIMI)

  • THEMIS

  • Tigris

  • Tigris

  • TIGRIS REGISTRY

  • TRA 2PB

  • Tranquility

  • VERTIS

  • VICTORIA

  • VICTORIA HF REGISTRY

  • Zerbini Registry